Guardant Health Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
GH$155.35-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (unaudited)
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| OPERATING ACTIVITIES: | ||
| Net loss | $(325,367) | $(292,406) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 31,933 | 32,013 |
| Operating lease costs | 23,357 | 22,146 |
| Stock-based compensation | 104,045 | 66,439 |
| Amortization of debt issuance costs | 1,935 | 1,931 |
| Amortization of discount on marketable debt securities | (2,815) | (10,913) |
| Unrealized and realized losses (gains) on marketable equity securities | 47,225 | (84,513) |
| Impairment of non-marketable equity securities and other related assets | — | 29,054 |
| Other | 2,372 | 334 |
| Cash effect of changes in operating assets and liabilities: | ||
| Accounts receivable, net | 316 | 8,360 |
| Inventory, net | (10,349) | (25,435) |
| Prepaid expenses and other current assets, net | (9,192) | (2,558) |
| Other assets, net | (1,561) | 2,280 |
| Accounts payable and accrued liabilities | (19,813) | 26,577 |
| Operating lease liabilities | (27,029) | (22,724) |
| Deferred revenue | 9,598 | 3,168 |
| Net cash used in operating activities | (175,345) | (246,247) |
| INVESTING ACTIVITIES: | ||
| Purchases of marketable debt securities | (307,323) | (629,902) |
| Maturities of marketable debt securities | 35,000 | 828,700 |
| Sales of marketable equity securities | 19,195 | — |
| Purchases of non-marketable equity securities and other related assets | (2,500) | (5,593) |
| Purchases of property and equipment | (16,210) | (16,409) |
| Net cash (used in) provided by investing activities | (271,838) | 176,796 |
| FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock upon exercise of stock options | 2,597 | 290 |
| Proceeds from issuances of common stock under employee stock purchase plan | 7,212 | 6,697 |
| Taxes paid related to net share settlement of restricted stock units | (7,658) | (8,112) |
| Proceeds from follow-on public offering | — | 402,500 |
| Payment of offering costs related to follow-on public offering | — | (20,478) |
| Other | (212) | 5,910 |
| Net cash provided by financing activities | 1,939 | 386,807 |
| Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | (75) | (1,941) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (445,319) | 315,415 |
| Cash, cash equivalents and restricted cash—Beginning of period | 1,133,687 | 141,948 |
| Cash, cash equivalents and restricted cash—End of period | $688,368 | $457,363 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $585,022 | $457,339 |
| Restricted cash – included in cash, cash equivalents and restricted cash | 103,346 | 24 |
| Total cash, cash equivalents and restricted cash | $688,368 | $457,363 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.